PofoliaShared via Pofolia

Head & Neck· 2012Q1· Review

Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region

Hisham Mehanna, T.J. Beech, T. Nicholson, Iman El‐Hariry et al.

Short summary

HPV prevalence in oropharyngeal cancer (OPC) significantly increased from 40.5% before 2000 to 72.2% between 2005-2009, while non-OPC prevalence remained stable at 21.8%.

AI-generated from the title and abstract; the full text is not read.

Key points

  • HPV prevalence in OPC rose significantly over time, from 40.5% (pre-2000) to 72.2% (2005-2009).
  • The gap in HPV prevalence between North America and Europe for OPC has closed.
  • HPV prevalence in non-OPC remained stable at 21.8% and did not increase over time.
  • The rate of increase in HPV-positive OPC was faster in Europe than in North America.

AI-generated from the title and abstract; the full text is not read.

Abstract

BACKGROUND: Little information has been reported on regional and time trends of human papillomavirus (HPV) prevalence rates of oropharyngeal cancer (OPC) and non-OPC. METHODS: The study consisted of a systematic review and meta-analysis using random effects logistic regression models. RESULTS: Overall HPV prevalence in OPC (47.7%; 95% confidence interval [CI], 42.9-52.5%) increased significantly over time: from 40.5% (95% CI, 35.1-46.1) before 2000, to 64.3% (95% CI, 56.7-71.3) between 2000 and 2004, and 72.2% (95% CI, 52.9-85.7) between 2005 and 2009 (p < .001). Prevalence increased significantly in North America and Europe, and the significant gap between them that existed before 2000 (50.7% vs 35.3%, respectively, p = .008) has now disappeared (69.7% vs 73.1%, respectively, p = .8). Prevalence in non-OPC (21.8%; 95% CI, 18.9-25.1%) has not increased over time (p = .97). CONCLUSIONS: The sharp increase in the proportion of HPV-positive OPC over the last decade has occurred at a faster rate in Europe compared with that in North America. In contrast, the relatively low prevalence of HPV in non-OPC remains unchanged.

The authors' abstract, as published at the source. Head & Neck, 2012 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Otorhinolaryngology

OtorhinolaryngologyMedicine